Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients

Abstract Background Interstitial pneumonitis (IP) is a severe adverse event in patients receiving immunotherapy. Although PD-1/PD-L1 inhibitors and bevacizumab have been widely used in patients with non-small cell lung cancer (NSCLC), the interaction between their combination and IP is less known. M...

Full description

Bibliographic Details

Published in:	Cancer Immunology, Immunotherapy
Main Authors:	Linling Wang, Yasi Xu, Yanyan Zhao, Bing Xia, Lucheng Zhu
Format:	Article
Language:	English
Published:	Springer 2025-10-01
Subjects:	Interstitial pneumonitis Checkpoint inhibitors Non-small cell lung cancer Bevacizumab Programmed death 1 Programmed cell death 1 ligand 1
Online Access:	https://doi.org/10.1007/s00262-025-04158-1